Days after announcing a reorganization plan to focus on deep learning and its “most important project,” the Biogen-partnered Alzheimer’s drug lecanemab, Eisai is shuttering its oncology unit H3 Biomedicine.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced it will be providing an update on its intratumoral E7766 clinical program for advanced solid tumors or lymphomas in a poster presentation at the 2021 American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) Virtual International Conference on Molecular Targets and Cancer Therapeutics being held on October 7-10, 2021.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of three posters at the 2020 San Antonio Breast Cancer Symposium (SABCS). The presentations include interim data from H3’s ongoing Phase 1/2 clinical development program, H3B-6545, a potential first-in-class, orally available Selective ER? Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of three posters at the 2020 San Antonio Breast Cancer Symposium (SABCS). The presentations include interim data from H3’s ongoing Phase 1/2 clinical development program, H3B-6545, a potential first-in-class, orally available Selective ER? Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer.
H3 Biomedicine, Inc. (H3), precision medicine research & development subsidiary of Eisai Co has announced the appointment of Antonio Gualberto, MD, PhD, to the position of Chief Medical Officer (CMO). Dr. Gualberto will oversee global clinical research & development for the H3 pipeline of clinical stage assets.